The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients
Jagdip S. Sidhu, MRCP*,
Dahlia Cowan, BSc* and
Juan-Carlos Kaski, MD, DSc, FACC*,*
* Coronary Artery Disease Research Unit, Cardiological Sciences, St. George's Hospital Medical School, London, United Kingdom.

View larger version (14K):
[in a new window]
|
Figure 1 Effect of rosiglitazone on E-selectin and von Willebrand factor levels. Paired results at baseline and after 12 weeks of treatment are shown in each treatment group. Boxes indicate mean values, and bars represent 95% confidence intervals. *p < 0.05 for the change in the rosiglitazone versus placebo group.
|
|

View larger version (13K):
[in a new window]
|
Figure 2 Effect of rosiglitazone on fibrinogen and log (CRP) levels. Paired results at baseline and after 12 weeks of treatment are shown in each treatment group. Boxes indicate mean values, and bars represent 95% confidence intervals. p < 0.005 for the change in the rosiglitazone versus placebo group.
|
|
|